Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Chronic Obstructive Lung Disease Clinical Trials

A listing of Chronic Obstructive Lung Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (60) clinical trials

The purpose of this study is to compare a FDA approved single therapy inhaler that combines 3 COPD medications to Spiriva for patient convenience. This study is about 3 months long and will consist of 6 office visits. All visits are conducted locally in Salt Lake City, Utah.


Utilizing Wearable Device to Observe the Clinical Response of COPD Patients Treated With Combined Bronchodilator and Home-based Pulmonary Rehabilitation Program

The prevalence of chronic obstructive pulmonary disease (COPD) has increased year by year and the estimated mortality rate by 2030 will be in the fourth place. Estimated global prevalence of COPD in the population over age 40 is about 9-10% of the population. In Taiwan, the prevalence is about 16%. ...


Clinical Trial of Efficacy and Safety of Rengalin in the Treatment of Cough in Patients With Chronic Obstructive Pulmonary Disease

The purpose of this study is to obtain additional data on efficacy and safety of Rengalin in the treatment of cough in patients with stable obstructive pulmonary disease


Effects of Liraglutide in Chronic Obstructive Pulmonary Disease

COPD is a common disease characterized by pulmonary inflammation, reduced pulmonary capacity, reduced physical activity and quality of life. Obesity is likewise a common disease characterized by inflammation, reduced physical activity and quality of life. Targeting both obesity and inflammation may turn out beneficial for patients with COPD and obesity, ...


Ultibro Versus Spiriva Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD

The foundation of COPD therapy is to combine inhaled therapy to optimize benefits as it was done several years ago by associating short-acting 2-agonists and muscarinic antagonist. The recent availability of once-daily LABA/LAMA fixed combination products makes this therapeutic strategy even more appealing and appears as a promising treatment option ...


The Effect of BEVESPI AEROSPHERE Therapy on Exercise Tolerance in COPD

Patients with chronic obstructive pulmonary disease (COPD) have obstruction to expiratory airflow, marked breathlessness, high dyspnea scores, and reduced exercise tolerance relative to age and gender matched non-smoking controls (Casaburi, 2009; Casaburi et al., 2014; Puente-Maestu et al., 2016). A prominent mechanism for exercise intolerance is thought to be dynamic ...


Targeted AntiBiotics for Chronic Obstructive Pulmonary Disease

P. aeruginosa represents a potentially significant cause of acute exacerbation of COPD (AECOPD) and is possibly associated with significant morbidity and mortality. Despite this, the role of P. aeruginosa in the course of COPD is less well characterized, and evidence based guidelines for management and treatment of the bacteria are ...


The Effect of Twice Daily vs. Once Daily Bronchodilation on Hyperinflation in COPD Patients During 24 Hours.

To study the effect of twice daily dual bronchodilation (Aclidinium Bromide/Formoterol Fumarate 340/12 mcg) versus once daily single bronchodilation (Tiotropium 'respimat' 5 mcg) in patients with COPD on 24-hour static and dynamic hyperinflation, spirometry respiratory symptoms and sleep quality.


Effects of Dual Bronchodilator Treatment on Cardiopulmonary Interactions in COPD

Prospective, proof-of-concept, single-dose study will be conducted using a randomized, double-blind, placebo-controlled, crossover design. Treatment will consist of a single dose of tiotropium 5mcg and olodaterol 5mcg via Respimat (Inspiolto)(TIO/OLO) or placebo; the order of treatment will be randomized. Submaximal cardiopulmonary exercise tests will be performed 1 hour after inhalation ...


Stage 1 Study of ARALAST NP and GLASSIA in A1PI

The purpose of this study is to conduct a pilot study to evaluate the safety and efficacy of weekly administration of Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy in subjects with A1PI deficiency and emphysema/ Chronic obstructive pulmonary disease (COPD).